Xilis is a biotechnology company developing a precision oncology platform that guides treatment decisions for oncologists to improve cancer care outcomes for patients and enables drug discovery and development with pharmaceutical companies. Xilis' proprietary MicroOrganoSphere™ (MOS) technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution. Using MOS and AI-driven algorithms, Xilis is developing a Xilis Response Score™ for the clinic, enabling oncologists to make informed and timely treatment decisions. Additionally, the MOS technology is speeding up the discovery and clinical development of new drug candidates.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/13/22	$19,000,000	Series A Extension	Alexandria Venture Investments Alix Ventures Catalio Capital Duke Angel Network EQT Life Sciences Felicis Ventures FPV Ventures GV Mubadala Capital Pear Ventures Two Sigma Ventures	undisclosed